Fexapotide triflutate| CAS#1609252-56-3 | benign prostatic hyperplasia

MedKoo Cat#: 414526 | Name: Fexapotide triflutate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fexapotide, also known as NX-1207, is used in the treatment of Benign Prostatic Hyperplasia. NX-1207 has selective pro-apoptotic properties, which induces focal cell loss in prostate leading to prostate volume reduction with both short- and long-term symptomatic improvement.

Chemical Structure

Fexapotide triflutate

CAS#1609252-56-3 (triflutate)

Theoretical Analysis

MedKoo Cat#: 414526

Name: Fexapotide triflutate

CAS#: 1609252-56-3 (triflutate)

Chemical Formula: C100H168F15N27O35S

Exact Mass: 2624.1677

Molecular Weight: 2625.63

Elemental Analysis: C, 45.75; H, 6.45; F, 10.85; N, 14.40; O, 21.33; S, 1.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

492447-54-8 (free base) 1609252-56-3 (triflutate)

Synonym

Fexapotide triflutate; NX1207; NX 1207; NX-1207

IUPAC/Chemical Name

(2S,5R,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S)-47-((2S,3S)-2-amino-3-methylpentanamido)-41,44-bis(3-amino-3-oxopropyl)-11,23-bis(4-aminobutyl)-14,26-di((S)-sec-butyl)-17-(2-carboxyethyl)-8,29-bis(3-guanidinopropyl)-32-(hydroxymethyl)-2,20,35-triisobutyl-38-isopropyl-5-(mercaptomethyl)-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46-pentadecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45-pentadecaazanonatetracontanedioic acid compound with 2,2,2-trifluoroacetic acid (1:5)

InChi Key

IBMWAUVJJROIMB-IWEBAUSJSA-N

InChi Code

InChI=1S/C90H163N27O25S.5C2HF3O2/c1-15-48(12)68(95)84(137)110-60(41-67(123)124)81(134)105-55(28-31-64(93)119)75(128)104-56(29-32-65(94)120)77(130)115-69(47(10)11)85(138)111-59(39-45(6)7)80(133)113-62(42-118)82(135)103-54(27-23-37-101-90(98)99)76(129)116-70(49(13)16-2)86(139)108-52(25-19-21-35-92)73(126)109-58(38-44(4)5)79(132)106-57(30-33-66(121)122)78(131)117-71(50(14)17-3)87(140)107-51(24-18-20-34-91)72(125)102-53(26-22-36-100-89(96)97)74(127)114-63(43-143)83(136)112-61(88(141)142)40-46(8)9;5*3-2(4,5)1(6)7/h44-63,68-71,118,143H,15-43,91-92,95H2,1-14H3,(H2,93,119)(H2,94,120)(H,102,125)(H,103,135)(H,104,128)(H,105,134)(H,106,132)(H,107,140)(H,108,139)(H,109,126)(H,110,137)(H,111,138)(H,112,136)(H,113,133)(H,114,127)(H,115,130)(H,116,129)(H,117,131)(H,121,122)(H,123,124)(H,141,142)(H4,96,97,100)(H4,98,99,101);5*(H,6,7)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-,69-,70-,71-;;;;;/m0...../s1

SMILES Code

CC(C)C[C@@H](C(O)=O)NC([C@H](CS)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H]([C@@H](C)CC)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@@H](C)CC)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is a common affliction among older men that can have significant impact on health-related quality of life. BPH is a progressive condition that can lead to complications including acute urinary retention (AUR) and to surgical intervention. There is an ongoing need for new, safe and effective treatments for BPH. Currently available therapies have significant safety and efficacy limitations. NX-1207 is a promising first-in-class drug currently in Phase III trials for the treatment of BPH.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 2,625.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ückert S, Kedia GT, Tsikas D, Simon A, Bannowsky A, Kuczyk MA. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World J Urol. 2020 Jun;38(6):1423-1435. doi: 10.1007/s00345-019-02933-1. Epub 2019 Sep 10. PMID: 31506747. 2: Lombardo R, Andersson KE, Tubaro A, De Nunzio C. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urol Nefrol. 2018 Dec;70(6):570-578. doi: 10.23736/S0393-2249.18.03233-2. Epub 2018 Oct 3. PMID: 30298711. 3: Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018 Jan;5(1):22-27. doi: 10.1016/j.ajur.2017.06.001. Epub 2017 Jun 9. PMID: 29379732; PMCID: PMC5780286. 4: Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, Stief CG, Woo HH, Gratzke C. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. Eur Urol. 2017 Dec;72(6):986-997. doi: 10.1016/j.eururo.2017.07.005. Epub 2017 Jul 19. PMID: 28734706. 5: Magistro G, Stief CG, Gratzke C. Minimal-invasive Therapie des benignen Prostatasyndroms [Minimally invasive treatment of benign prostatic hyperplasia]. Urologe A. 2016 Nov;55(11):1419-1432. German. doi: 10.1007/s00120-016-0249-4. PMID: 27761589. 6: Nair SM, Pimentel MA, Gilling PJ. Evolving and investigational therapies for benign prostatic hyperplasia. Can J Urol. 2015 Oct;22 Suppl 1:82-7. PMID: 26497348. 7: Magistro G, Stief CG, Gratzke C. New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol. 2015 Aug;12(8):461-71. doi: 10.1038/nrurol.2015.169. Epub 2015 Jul 21. PMID: 26195444. 8: Ebbing J, Bachmann A. Anesthesia-free procedures for benign prostate obstruction: worth it? Curr Opin Urol. 2015 Jan;25(1):32-9. doi: 10.1097/MOU.0000000000000123. PMID: 25340879. 9: Andersson KE. Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2015 Jan;25(1):12-8. doi: 10.1097/MOU.0000000000000122. PMID: 25333915. 10: Russo A, La Croce G, Capogrosso P, Ventimiglia E, Colicchia M, Serino A, Mirone V, Damiano R, Montorsi F, Salonia A. Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opin Pharmacother. 2014 Nov;15(16):2319-28. doi: 10.1517/14656566.2014.955470. Epub 2014 Aug 28. PMID: 25164497. 11: Kunit T, Lusuardi L. An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol. 2014 Jul 12;6:67-70. doi: 10.2147/RRU.S46047. PMID: 25157337; PMCID: PMC4103918. 12: Füllhase C, Soler R, Gratzke C. New strategies in treating male lower urinary tract symptoms. Curr Opin Urol. 2014 Jan;24(1):29-35. doi: 10.1097/MOU.0000000000000003. PMID: 24285261. 13: Chung A, Woo HH. What's truly minimally invasive in benign prostatic hyperplasia surgery? Curr Opin Urol. 2014 Jan;24(1):36-41. doi: 10.1097/MOU.0000000000000006. PMID: 24247171. 14: Bschleipfer T, Bach T, Gratzke C, Madersbacher S, Oelke M. Intraprostatische Injektionstherapien beim benignen Prostatasyndrom [Intraprostatic injection therapy in patients with benign prostatic syndrome]. Urologe A. 2013 Mar;52(3):354-8. German. doi: 10.1007/s00120-012-3091-3. PMID: 23435646. 15: Andersson KE. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol. 2013 Apr;47(2):83-90. doi: 10.3109/00365599.2012.752404. Epub 2013 Jan 3. PMID: 23281591. 16: Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011 Nov;2(6):377-83. doi: 10.1177/2040622311423128. PMID: 23251763; PMCID: PMC3513892. 17: Arenas da Silva LF, Schönthaler M, Cruz F, Gratzke C, Zumbe J, Stenzl A, Amend B, Sievert KD. Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann [New treatment strategies for male lower urinary tract symptoms]. Urologe A. 2012 Dec;51(12):1697-702. German. doi: 10.1007/s00120-012-3032-1. PMID: 23139025. 18: Lusuardi L, Hruby S, Janetschek G. New emerging technologies in benign prostatic hyperplasia. Curr Opin Urol. 2013 Jan;23(1):25-9. doi: 10.1097/MOU.0b013e32835abd34. PMID: 23138466. 19: Hashim H, Abrams P. Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs. 2010 Jun;15(2):159-74. doi: 10.1517/14728211003716459. PMID: 20446824. 20: Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2010 Feb;19(2):305-10. doi: 10.1517/13543780903555196. PMID: 20050813.